Mobix Labs and Peraso Engage in Talks for Possible Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Confidentiality Agreement: Mobix Labs has entered into a mutual confidentiality agreement with Peraso to facilitate discussions regarding a potential acquisition.
Strategic Collaboration: The agreement aims to create a structured framework for the exchange of information, focusing on a strategic combination of both companies' technologies.
Leadership Insight: Phil Sansone, CEO of Mobix Labs, expressed optimism about the collaboration, highlighting the potential benefits of merging Peraso's wireless expertise with Mobix's connectivity solutions.
Previous Offer: This new cooperative approach follows Mobix Labs' unsolicited acquisition offer to Peraso made in June 2025.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like MOBX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on MOBX
About MOBX
Mobix Labs, Inc. designs, develops and sells components and systems for advanced wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. The Company's solutions are used in the consumer commercial, industrial, automotive, medical, aerospace, defense and other markets. The Company's wireless systems solutions include products for advanced RF and millimeter wave (mmWave) 5G communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the commercial, industrial, and defense and aerospace sectors. Its interconnect products, including EMI filter inserts and filtered and non-filtered connectors, are designed for and are used in aerospace, military, defense and medical applications. Its True Xero active optical cables (AOCs) are designed to deliver fiber optic connectivity for a range of applications, including 5G infrastructure, autonomous vehicles and remote medical systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results
- Trial Success: Alumis Inc. achieved all primary and secondary endpoints in its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, resulting in a 132% surge in stock price, indicating strong market potential and investor confidence.
- Market Reaction: Following the announcement, shares skyrocketed to $19.30, reflecting a positive investor response to the clinical data, which may attract more institutional investors and further enhance the company's market capitalization.
- Industry Impact: Alumis's success provides a new treatment option in the biopharmaceutical industry, particularly in the psoriasis sector, potentially prompting other companies to increase R&D investments and drive overall industry innovation.
- Future Outlook: With the successful clinical trials, Alumis is expected to accelerate the drug's market entry, likely leading to significant revenue growth while strengthening its position in the highly competitive biopharmaceutical market.
Continue Reading
AngioDynamics Surpasses Expectations with $79.4M Sales and Break-Even EPS
- Earnings Beat: AngioDynamics reported an adjusted EPS of $0.00 for Q2, exceeding market expectations of a 10-cent loss, indicating a significant improvement in the company's profitability.
- Sales Growth: The company achieved sales of $79.4 million, surpassing the market forecast of $76.3 million, demonstrating strong product demand and driving overall performance enhancement.
- Positive Market Reaction: Following the earnings release, AngioDynamics' stock received favorable attention from investors, reflecting confidence in its future growth potential, which may further drive stock price appreciation.
- Optimistic Industry Outlook: With the recovery of the medical device sector, AngioDynamics' robust performance could attract more investor interest, strengthening its position in a competitive market.
Continue Reading